Interv Akut Kardiol 2011; 10(5-6): 240-244

Pharmacotherapy and the aortic stenosis progression

Roman Čerbák

Centrum kardiovaskulární a transplantační chirurgie Brno

Aortic stenosis is the most frequent and the most operated heart valve disease. The current capabilities and limitations of the pharmacological

treatment are provided. Hypolipidemic treatment of the disease by means of statins did not fulfill the expectations, the big

randomized studies did not include the earliest stages of the disease. The success in treatment by bisphosphonates was found only in

retrospective studies. The association of bisphosphonates with atrial fibrillation remains uncertain. The treatment of aortic stenosis

by means of inhibitors converting the angiotenzin (ACEi) does not prove definite results and new perspective studies are expected.

Inflammatory changes were detected both in early and in late stages of the disease. The dysfunctional anti-inflammatory mechanism of

the aortic stenosis was found. Currently there is no pharmacotherapy for the disease which would prevent its progression. The surgical

aortic valve replacement (AVR) or transfemoral (transapical) implantation of bioprothesis (TAVI) are the only successfull, validated and

recomended treatment procedures.

Keywords: statins in aortic stenosis, bisphosphonates in aortic stenosis, bisphosphonates and atrial fibrillation, ACEI in aortic stenosis, inflammatory changes in aortic stenosis, ICAM and VCAM and aortic stenosis, dysfunctional mechanisms of anti-inflammation

Published: November 1, 2011  Show citation